PLE inhibits IMQ-induced inflammatory in mice, and the contents of TNF-α (A) and IL-17A (B). by Xiaoqiang Huang (1457860)

Mean plasma concentration-time profiles of paeoniflorin and paeonol comparing low and high repeated doses of MC in DNBS-induced colitis rats. by Jin-Hwa Kim (101817)

Changes associated with kidney fibrosis and effects of MN705 treatment on TGF- by Wencheng Jin (13136262)

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

Changes related to kidney staining in UUO mouse model. by Wencheng Jin (13136262)

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Changes associated with kidney fibrosis in TGF- by Wencheng Jin (13136262)

The screening process of MN705. by Wencheng Jin (13136262)

Validation of MN705 treatment effects in human proximal tubular epithelial cells during TGF- by Wencheng Jin (13136262)

Age-specific burden of IHD attributable to HSBP for males and females in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Global burden of IHD attributable to HSBP from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific estimated annual percentage changes in DALYs and death rates for 21 regions from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. by Zhenhua Zhuang (11192745)

Subjects:

Effect of MN705 treatment on TGF- by Wencheng Jin (13136262)

Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…</p><p>Results</p><p>During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of −0.36% in HbA1c levels between the groups (95% CI: −0.54 – −0.19, P < 0.01). …”

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: